Skip to content
value.today
I-Therapeutix Inc. logo

I-Therapeutix Inc.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2006
Total raised
$51 M
5 rounds on record
Latest round
$9 M
May 2013
First round on record
Oct 2006
Today
Went public
See the company page

I-Therapeutix Inc. is listed today as Ocular Therapeutix, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of I-Therapeutix Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2013$9 MNo. 5$2 to $10 million

I-Therapeutix Inc.: Raise no. 5, May 2013

Investors in this round

2 investors had bought by the notice of Jun 10, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for I-Therapeutix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
$2,000,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Crane · Executive Officer, Director
  • Amarpreet Sawhney · Executive Officer, Director
  • Charles Warden · Executive Officer, Director
  • Farhad Khosravi · Executive Officer, Director
  • James Garvey · Executive Officer, Director
  • Brian Levy · Director
  • Richard Lindstrom · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Amarpreet Sawhney, President. Source: SEC Form D, newest notice filed Jun 10, 2013. Read the notice at the SEC.

equitySEC
Feb 2011$14 MNo. 4$10 to $50 million

I-Therapeutix Inc.: Raise no. 4, Feb 2011

Investors in this round

9 investors had bought by the notice of Feb 8, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for I-Therapeutix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
$18,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Crain · Executive Officer, Director
  • Amarpreet Sawhney · Executive Officer, Director
  • Bernard Haffey · Executive Officer, Director
  • Charles Warden · Executive Officer, Director
  • Daniel Myers · Executive Officer, Director
  • Farhad Khosravi · Executive Officer, Director
  • James Garvey · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven J. Cagnetta, Secretary. Source: SEC Form D, newest notice filed Feb 8, 2011. Read the notice at the SEC.

equitySEC
Jun 2009$21 MNo. 3$10 to $50 million

I-Therapeutix Inc.: Raise no. 3, Jun 2009

Investors in this round

29 investors had bought by the notice of Jan 12, 2011: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for I-Therapeutix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Crain · Executive Officer, Director
  • Amarpreet Sawhney · Executive Officer, Director
  • Bernard Haffey · Executive Officer, Director
  • Charles Warden · Executive Officer, Director
  • Daniel Myers · Executive Officer, Director
  • Farhad Khosravi · Executive Officer, Director
  • James Garvey · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven J. Cagnetta, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Jan 12, 2011. Read the notice at the SEC.

equity, optionsSEC
Jan 2008$6 MNo. 2$2 to $10 million

I-Therapeutix Inc.: Raise no. 2, Jan 2008

Investors in this round

13 investors had bought by the notice of Jul 1, 2009: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for I-Therapeutix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
$1,000
What was sold
options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amarpreet Sawhney · Executive Officer, Director
  • Steven Cagnetta · Executive Officer
  • Alan Crain · Director
  • Charles Warden · Director
  • Farhad Khosravi · Director
  • Samuel Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven J. Cagnetta, Secretary. Source: SEC Form D, newest notice filed Jul 1, 2009. Read the notice at the SEC.

optionsSEC
Oct 2006$1 MNo. 1Under $2 million

I-Therapeutix Inc.: Raise no. 1, Oct 2006

Investors in this round

18 investors had bought by the notice of Jul 1, 2009: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for I-Therapeutix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,000
What was sold
options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amarpreet Sawhney · Executive Officer, Director
  • Steven Cagnetta · Executive Officer
  • Charles Warden · Director
  • Farhad Khosravi · Director
  • Samuel Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven J. Cagnetta, Secretary. Source: SEC Form D, newest notice filed Jul 1, 2009. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Ocular Therapeutix, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration revenue $130,000 (0%).

    Annual report (SEC XBRL) · Dec 2025

  • I-Therapeutix Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2013).

    SEC Form D · Jun 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2013

Products and services#

No products or services of I-Therapeutix Inc. are on record.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in I-Therapeutix Inc.
InvestorKindAmountRoundRoleSource
Amarpreet SawhneyPersonnot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2014)SEC Form 3
Ascension Health Ventures II, LLCVenture capitalnot statednot statedHeld Series D and D-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
CHV II, L.P.Fund or asset managernot statednot statedHeld Series D and D-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Richard L. LindstromPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2014)SEC Form 3
SV Life Sciences Fund IV (GP), L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
SV Life Sciences Fund IV, L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
SV Life Sciences Fund IV Strategic Partners, L. P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Svlsf IV, LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Side Fund III, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Venture Capital III, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 29 investors.

Largest shareholders today

Institutions holding Ocular Therapeutix, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by I-Therapeutix Inc.
NameRoleNamed in
Alan CraneExecutive officerJun 2013
Amarpreet SawhneyExecutive officerJun 2013
Charles WardenExecutive officerJun 2013
Farhad KhosraviExecutive officerJun 2013
James GarveyExecutive officerJun 2013
Alan CrainExecutive officerFeb 2011
Bernard HaffeyExecutive officerFeb 2011
Daniel MyersExecutive officerFeb 2011
Steven CagnettaExecutive officerJul 2009
Alan CraneDirectorJun 2013
Amarpreet SawhneyDirectorJun 2013
Brian LevyDirectorJun 2013
Charles WardenDirectorJun 2013
Farhad KhosraviDirectorJun 2013
James GarveyDirectorJun 2013
Richard LindstromDirectorJun 2013
Alan CrainDirectorFeb 2011
Bernard HaffeyDirectorFeb 2011
Daniel MyersDirectorFeb 2011
Samuel WuDirectorJul 2009

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.